Analyst Research Report Snapshot

Title:

ABLYNX - SAFE TO INHALE

Price:

$10.00

Provider:

Edison Investment Research

Date:

20 Sep 2012

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ABLX.BR

Available for Immediate Download
Summary:

The first clinical trial with an inhaled Nanobody has been successfully completed. ALX-0171, developed to treat respiratory syncytial virus (RSV) infections, was well tolerated and no immunogenicity was detected. Additional Phase I studies are planned before the Nanobody enters paediatric Phase II development, and Ablynx aims to partner the product before then. These results further highlight the potential of Nanobodies, as monoclonal antibodies cannot be delivered in a similar way.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.